Merdrignac, LoreLaniece Delaunay, CharlotteVerdasca, NunoVega-Piris, LorenaO'Donnell, JoanSève, NoémieTrobajo-Sanmartín, CaminoBuda, SilkeHooiveld, MariëtteRodrigues, Ana PaulaTúri, GergőLatorre-Margalef, NeusMlinarić, IvanLazar, MihaelaMaurel, MarineCastrillejo, DanielBennett, CharleneRameix-Welti, Marie-AnneMartínez-Baz, IvánDürrwald, RalfMeijer, AdamMelo, AryseOroszi, BeatrixHagey, Tove SamuelssonKurečić Filipović, SanjaDijkstra, FrederikaGomez, VerónicaBacci, SabrinaKaczmarek, MarlenaKissling, EstherVEBIS Primary Care Vaccine Effectiveness Group2025-03-112025-03-112024-11Merdrignac L, Laniece Delaunay C, Verdasca N, Vega-Piris L, O'Donnell J, Sève N, Trobajo-Sanmartín C, Buda S, Hooiveld M, Rodrigues AP, Túri G, Latorre-Margalef N, Mlinarić I, Lazar M, Maurel M, Castrillejo D, Bennett C, Rameix-Welti MA, Martínez-Baz I, Dürrwald R, Meijer A, Melo A, Oroszi B, Hagey TS, Kurečić Filipović S, Dijkstra F, Gomez V, Bacci S, Kaczmarek M, Kissling E; VEBIS Primary Care Vaccine Effectiveness Group. Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023-1 March 2024. Influenza Other Respir Viruses. 2024 Nov;18(11):e70009.1750-2640https://hdl.handle.net/20.500.12105/26417We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection among adults aged ≥ 65 years during the 2023/2024 JN.1 lineage-predominant period in a European multi-country test-negative case-control study at primary care level. We estimated VE adjusted by study site, age, sex, chronic conditions and onset date. We included 220 cases and 1733 controls. The VE was 48% (95% CI: 12-71), 23% (95% CI: -11-48) and 5% (95% CI: -92-56) among those with symptom onset 1-5, 6-11, and ≥ 12 weeks after vaccination, respectively. XBB.1.5 vaccine provided short and moderate protection against JN.1 symptomatic infection.engVoRhttp://creativecommons.org/licenses/by/4.0/COVID‐19SARS‐CoV‐2Case–control studyMulti‐country studyPrimary careTest‐negative designVaccine effectivenessAgedAged, 80 and overCOVID-19 VaccinesCOVID-19Case-Control StudiesEuropeFemaleHumansMalePrimary Health CareSARS-CoV-2VaccinationVaccine EfficacyAttribution 4.0 International395237811811e7000910.1111/irv.700091750-2659Influenza and other respiratory virusesopen access